Our group has previously described the clinical aspects of the BRAF V600E mutation in CRC, which has been correlated with rapidly progressive multimetastatic disease, poor performance status, advanced age, peritoneal disease and low probability of secondary metastasectomy (7). This evidence concerns the gene BRAF and colorectal carcinoma.